An interventional study of Insul-In This Together in Diabetes Type 1, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 1 by Stanford University — 4 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Stanford University.
Among the 31 studies in Diabetes Mellitus, Type 1 by Stanford University, this one is the 3rd largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2028, is one of 23 with no phase, and was the 31st registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 31 studies in Diabetes Mellitus, Type 1 by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 2–26
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 12 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2028.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 24 across the 28 interventional studies, 30 across the 3 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07501338Stanford UniversityEarly Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D | 2027-03 |
| NCT06329375Stanford UniversityFood Insecurity Reduction & Strategy Team | 2027-04-15 |
| NCT07226583Stanford UniversityUsing a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 1 by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the "Insul-In This Together" family program works to improve outcomes for adolescents living with type 1 diabetes. It will also learn about how the program influences diabetes-related factors, including parenting. The main questions it aims to answer are:
Does this program improve glycemic (blood glucose) outcomes? Does this program improve adolescent quality of life related to diabetes? Researchers will offer the program to all participating families, with one group receiving the program right after enrollment and another group receiving the program 6 months later.
Adolescent and parent participants will:
Attend 8 weekly 30-minute videoconference sessions with an interventionist Complete online surveys, share diabetes device data, and conduct at-home A1c tests 3-5 times over a 12-month period
The proposed study is a nationwide randomized controlled trial with 200 adolescents ages 12-17 living with type 1 diabetes for at least six months who are US residents and their parents. Participants will be randomized 1:1 to either the intervention condition (offered the intervention immediately post-baseline) or the waitlisted control condition (offered the intervention after completing the 6-month follow-up). The primary outcome endpoint will be 3-month post-baseline, based on prior findings. This cross-over design will support recruitment and retention and offer all participants the opportunity to receive this empirically supported program, while maintaining an experimental comparison group. The revised intervention includes eight 30-minute weekly sessions to be delivered to each parent-adolescent dyad by a trained interventionist. Didactic and interactive content targets parental monitoring, involvement strategies, collaborative problem-solving, and communication across six sessions with two glycemic sessions that focus on glucose monitoring, data interpretation, and strategies to increase/optimize technology use. Data will be gathered via adolescent and parent report, continuous glucose monitoring (CGM) and other device data, and at-home HbA1c test kits. We will assess intervention outcomes, differential intervention responses, and key drivers of change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Offered the intervention immediately after Baseline data collection
Behavioral: Insul-In This Together
Offered the intervention after 6-Month Post-Baseline data collection
Behavioral: Insul-In This Together
The "Insul-In This Together" intervention consists of eight weekly 30-minute sessions. Each adolescent-parent dyad (an adolescent with corresponding parent/caregiver) meets remotely with an interventionist (not in groups). The structure of adolescents and parents receiving the intervention as a single dyad (not in groups) offers space to discuss sensitive topics and flexibility to accommodate variability in families' schedules. Intervention content targets diabetes-related parental monitoring, involvement, and conflict with a focus on communication and problem-solving skills. Diabetes technology use is addressed related to shared goals, expectations, and communication based on each family's current use.
Adolescent diabetes-related quality of life
The Type 1 Diabetes and Life (T1DAL) survey is a 23-item scale with a teen version (ages 12-17) and a young adult version (ages 18-25) that capture quality of life related to living with diabetes (for those who turn 18 during the study).
Time frame: From Baseline (post enrollment) to 12-month post-baseline
Percent time-in-range (TIR)
TIR is strongly linked to risk of health complications and offers valuable insights beyond hemoglobin A1c, particularly.13 Percent time spent in target range (70-180mg/dL) will be calculated based on continuous glucose monitoring (CGM) data captured in a 14-day window. At least 10 days of data will be required within the 14-day window to be included in analyses.
Time frame: From baseline (post enrollment) to 12-month post-baseline
Hemoglobin A1c
HbA1c results will be gathered based on at-home test kits provided and analyzed by University of Minnesota.
Time frame: From baseline (post enrollment) to 12-month post-baseline
Adolescent diabetes distress
The Problem Areas in Diabetes questionnaire (PAID) is a 20-item scale of emotional responses related to diabetes distress among adolescents.
Time frame: From baseline (post enrollment) to 12-month post-baseline
Parent diabetes distress
The Parent Diabetes Distress Scale (P-DDS) is a 20-item measure of diabetes related distress among parents of teens with diabetes.
Time frame: From Baseline (post enrollment) to 12-month post-baseline
Plan to share: Yes — De-identified individual participant data may be shared with qualified researchers upon reasonable request after publication of the primary results. Requests will be reviewed by the study team and will require a scientifically sound proposal, institutional approvals as applicable, and a data use agreement that prohibits re-identification or onward sharing. Data sharing will be limited to information that can be provided without compromising participant privacy or confidentiality.
No publications or documents are linked to this record.
Start is estimated for Jan 2028; primary completion for Dec 2031, 47 months later.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 47 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.